Risk factors for mild cognitive impairment in Parkinson disease: a systematic review and meta-analysis

Yaodan Zhang1, Fang Chen2, Fengchun Ren3

  • 1Department of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

PubMed
Abstract

Insights

Mild cognitive impairment (MCI) in Parkinson's disease (PD) is linked to older age, later onset, and longer duration. Higher education offers protection, while disease severity increases risk.

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Mild cognitive impairment (MCI) is a prevalent non-motor symptom in Parkinson's disease (PD), often preceding dementia.
  • Risk factors for MCI in PD are not consistently established, necessitating comprehensive analysis.

Purpose of the Study:

  • To conduct a systematic review and meta-analysis to identify demographic and clinical risk factors for MCI in Parkinson's disease.
  • To synthesize existing data to provide a clearer understanding of MCI determinants in PD patients.

Main Methods:

  • Systematic review and meta-analysis adhering to PRISMA guidelines.
  • Searched electronic databases using MeSH terms and keywords, with multi-step screening by independent reviewers.
  • Data extraction and quality assessment using the Newcastle-Ottawa Scale; meta-analyses performed using Comprehensive Meta-Analysis (v2).

Main Results:

  • Older age, later age at PD onset, and longer disease duration were significant risk factors for MCI.
  • Higher educational attainment demonstrated a protective effect against MCI in PD.
  • Increased disease severity (UPDRS, Hoehn and Yahr scales) was significantly associated with higher MCI risk; gender was not a significant factor.

Conclusions:

  • Advanced age, later disease onset, longer disease duration, and greater PD severity are key determinants of MCI.
  • Findings underscore the importance of early detection and proactive management strategies for MCI in Parkinson's disease.
  • Identifying these risk factors can aid in guiding clinical decisions and interventions for PD patients.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
526